soul trial oral semaglutide cardiovascular outcomes trial results A emulation in Nature Medicine shows that treatment with and tirzepatide showed similar levels of benefit on in people at elevated cardiovascular risk with obesity and diabetes. Link Comparative cardiovascular outcomes of semaglutide

For patients with diabetes, retinopathy status should be evaluated before initiating semaglutide

Interesting update, retatrutide shows ~30% weight loss with metabolic benefits, highlighting its potential as a next-generation obesity therapy.

Available via IV therapy or Intramuscular injection Medications shipped directly to your home Administered by a licensed nurse Clients report improvements in focus, sleep, and overall vitality, benefiting from the anti-aging effects of NAD+ therapy.

AMPK activity is also allosterically regulated by AMP binding to the subunit (Figure 3)

The TRIUMPH-2 trial will evaluate the efficacy and safety of retatrutide in participants with T2DM who are obese or overweight, including a subset of participants who have obstructive sleep apnea (OSA)